<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071031</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-v-001</org_study_id>
    <nct_id>NCT01071031</nct_id>
  </id_info>
  <brief_title>HIV Vaccine Study in HIV Positive Patients</brief_title>
  <official_title>A Multicentre, Two Stage, Randomised, Double Blind Study of the Safety, Tolerability and Immunogenicity of a Human Immunodeficiency Virus (HIV) Vaccine Candidate, HIV-v</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PepTcell Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PepTcell Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to see whether a single vaccination (injection) with the
      investigational HIV vaccine is safe and effective in patients who are HIV positive but have
      not yet begun anti-retroviral therapy. As this is an exploratory study, four different dose
      formulations of HIV vaccine will be investigated.

      This study will evaluate whether or not the HIV vaccine is able to reduce the HIV viral load
      (number of HIV virus particles in the blood) and increase or slow the decline in CD4 T cell
      count.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of a screening period of 3 to 21 days before vaccination on Day 0 and
      a double-blind treatment period of 28 days with a follow up period of 5 months. Prior to
      conducting any study-related procedures, subjects will provide written informed consent.
      During screening, eligibility will be assessed, a medical history will be taken, a complete
      physical examination will be performed and vital signs will be measured. Blood samples will
      be taken for the assessment of HCV and HBV status. Further samples will be taken for CD4 and
      HIV load, haematology, biochemistry, urinalysis and a 12-lead electrocardiographic (ECG)
      assessment will be carried out. A self-assessment diary card will be used by subjects between
      Day 0 and Day 28 to record any AEs.

      On Days 7, 14, 21 and 28 an AE interview will be conducted, concomitant medications and vital
      signs will be recorded and a physical examination will be performed. Samples will be
      collected for haematology, clinical chemistry and urinalysis. In addition, samples will be
      collected for CD4 T cell count and HIV viral load at days 14 and 28 after vaccination. A
      sample will be collected for immunogenicity on Day 28.

      All patients will attend follow-up visits at Weeks 8, 12, 16, 20 and 24 at which a physical
      examination and examination of the injection site will be performed and vital signs measured.
      Samples will be collected for haematology, biochemistry, urinalysis CD4 T-cell count and HIV
      viral load. Blood samples for immunogenicity testing will be collected at Weeks 12 and 24.

      Stage I: Sequential, non-randomised, single blind, parallel group. Five male HIV-1 positive
      volunteers will be vaccinated in a sequential, non-randomised single blind fashion. They will
      each receive one of the five possible active study treatments (WFI only, adjuvant only, low
      dose + WFI, low dose + adjuvant, high dose + WFI and high dose + adjuvant). Each of these
      five patients will be observed as in-patients for 24 hours after vaccination and vaccinations
      will be performed in a sequential manner with at least 48 hours observation of each patient
      before vaccination of the next patient is commenced.

      Following completion of the '28 day treatment follow up' by the five Stage I subjects a
      Safety Committee will review the safety and tolerability data for these subjects and will
      make a recommendation for continuing or discontinuing recruitment and any changes that may be
      required in the conduct of the study. Subject to a positive decision from the Safety
      Committee the remaining subjects will be recruited into Stage II of the study.

      Stage II: randomised, double-blind group 50 male HIV-1 positive volunteers will be randomised
      to one of five possible treatment groups. Following completion of the Day 1 Visit by the
      first five subjects in Stage II the Safety Committee will review the blinded safety and
      tolerability data for these subjects. Subject to acceptable safety and tolerability, the
      centres will be allowed to continue recruitment for the rest of the planned cohort.

      After 25 Stage II subjects have completed the Day 1 Visit a Safety Committee will review the
      blinded data generated and will make a recommendation for continuing or discontinuing
      recruitment and any changes that may be required in the conduct of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate the safety and tolerability of the PepTcell HIV vaccine by analysis of safety data including changes in HIV load and CD4 T cell count.</measure>
    <time_frame>Pre-vaccination, days 1, 2, 7, 14, 21 and 28 after vaccination and weeks 8, 12, 16, 20 and 24 after vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose HIV-v with water for injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose HIV-v with adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose HIV-v with water for injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose HIV-v with adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group: adjuvant only or water for injection only</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIV-v (Low Dose)</intervention_name>
    <description>Low Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences) with water for injection or adjuvant
Administration: A single subcutaneous injection</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIV-v (High Dose)</intervention_name>
    <description>High Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences with water for injection or adjuvant
Administration: A single subcutaneous injection</description>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIV-v (Control)</intervention_name>
    <description>Adjuvant only or Water for injection only
Administration: A single subcutaneous injection</description>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subjects age 18 - 50 years inclusive with HIV-1 infection

          -  Documented as HIV positive, with viral loads higher than 5,000 copies per millilitre
             of blood, but less than 500,000 using either a branched DNA test, or an RT-PCR test

          -  CD4 T cell count &gt;350/mm3

          -  Clinically stable in the opinion of the investigator and not expected to require
             anti-retroviral therapy during the course of the study

          -  No evidence of any AIDS defining illness

          -  Subjects with male or female partners must agree to use a barrier method of protection
             against disease transmission during intercourse (e.g. condom).

          -  Subjects whose female partners are of child-bearing potential must also agree to use a
             second contraceptive method (e.g. spermicidal agent, IUD, hormonal contraceptive) in
             addition to a condom for the duration of the study.

          -  Provide written informed consent to participate in the study and be willing to comply
             with all study procedures.

        Exclusion Criteria:

          -  Participation in a clinical trial or receipt of an experimental therapy within 30 days
             prior to study dosing

          -  Receipt of another vaccine 30 days before or 30 days after HIV-v

          -  Currently receiving anti-viral, anti-retroviral therapy or any chronic anti-infective
             therapy

          -  Receiving, or have received over the previous two weeks, any treatment that might
             modulate the immune response after vaccination, including, but not limited to,
             immunosuppressive therapy and systemic corticosteroids

          -  Suffers from a disease or is undergoing treatment that can affect immune response such
             as systemic or high dose inhaled corticosteroids (&gt;800Âµg/day beclometasone or
             equivalent), radiation treatment or cytotoxic drugs

          -  Received a blood transfusion or immunoglobulins within 90 days prior to study entry

          -  Patients on inhaled corticosteroids for asthma or other respiratory conditions

          -  Subjects having an infective exacerbation during the screening process as defined as a
             requirement of inhaled, oral, or intravenous antibiotics prior to the first study dose
             will be excluded

          -  Use of non-steroidal anti-inflammatory drugs (NSAIDs) or any over-the-counter product,
             herbal product, diet aid, hormone supplement, etc., within 14 days prior to
             vaccination or any planned administration of these products over the course of the
             first 28 days after vaccination (unless approved by both the Principal Investigator
             and the Sponsor)

          -  Patients with Hepatitis B or C co-infection (though serological evidence of previous
             hepatitis C infection with no evidence of carrier status is acceptable)

          -  Suffers from or has a history of significant neurological, cardiovascular, pulmonary
             (including asthma), hepatic, metabolic, rheumatic, autoimmune, haematological or renal
             disorder

          -  Subjects with clinically significant out of range laboratory values as stated in
             Section 8.6 of the protocol

          -  Patients with a history of significant or allergic reaction to vaccines

          -  Patients with a known or suspected dependence on illicit drugs or alcohol and those
             undergoing illicit drug replacement programmes

          -  Is direct employee of the study site or monitoring CRO
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Boffito, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Stephen's Aids Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stuart Robinson</last_name>
    <role>Study Director</role>
    <affiliation>PepTcell Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Elton John Centre, Sussex House,</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 1ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grahame Hayton Unit, Ambrose King Centre, Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Stephen's Centre, Chelsea and Westminster Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Manchester General Hospital, Department for Infectious Diseases</name>
      <address>
        <city>Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>February 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2010</study_first_posted>
  <last_update_submitted>September 25, 2012</last_update_submitted>
  <last_update_submitted_qc>September 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2012</last_update_posted>
  <responsible_party>
    <name_title>Dr. Stuart Robinson, Head of Business Development</name_title>
    <organization>PepTcell Limited</organization>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Human Immunodeficiency Virus</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Vaccine</keyword>
  <keyword>CD4</keyword>
  <keyword>Viral Load</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

